The downregulation of anti-cancer responses may be a key activator for the inflammatory pathways characterized by the elevated concentrations of CRP, which are important for the development of several malignancies (Hojman et al., 2011; Pedersen and Febbraio, 2012; Aoi et al., 2013). This evidence concerns the gene CRP and cancer.